The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ELCC 2018 | Clinical trial data for TKIs in ALK-rearranged NSCLC

Name: Clinical trial data for TKIs in ALK-rearranged NSCLC
Uploaded: 2018-04-11T00:00:00.000Z
Duration: 1 min 48 s
Description: Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses results from recent clinical trials exploring the efficacy of different tyrosine kinase inhibitors (TKIs) on ALK-rearranged non-small cell lung cancer (NSCLC) at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

Silvia Novello • 11 Apr 2018

ELCC 2018

Lung Cancer Non-Small Cell Lung Cancer Alectinib Ceritinib

ALEX ASCEND-4 PROFILE 1014

Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses results from recent clinical trials exploring the efficacy of different tyrosine kinase inhibitors (TKIs) on ALK-rearranged non-small cell lung cancer (NSCLC) at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.